Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease

Takao Yasuhara, Tetsuro Shingo, Isao Date

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Many studies using animals clarify that glial cell line-derived neurotrophic factor (GDNF) has strong neuroprotective and neurorestorative effects on dopaminergic neurons. Several pilot studies clarified the validity of continuous intraputaminal GDNF infusion to patients with Parkinson's disease (PD), although a randomized controlled trial of GDNF therapy published in 2006 resulted in negative outcomes, and controversy remains about the efficacy and safety of the treatment. For a decade, our laboratory has investigated the efficacy and the most appropriate method of GDNF administration using animals, and consequently we have obtained some solid data that correspond to the results of clinical trials. In this review, we present an outline of our studies and other key studies related to GDNF, the current state of the research, problems to be overcome, and predictions regarding the use of GDNF therapy for PD in the future. Copyright

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalActa Medica Okayama
Volume61
Issue number2
Publication statusPublished - Apr 2007

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Parkinson Disease
Animals
Therapeutics
Dopaminergic Neurons
Neuroprotective Agents
Neurons
Randomized Controlled Trials
Clinical Trials
Safety
Research

Keywords

  • Cell transplantation
  • Clinical trial
  • Encapsulation
  • Gene therapy
  • Neurodegenerative disease

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease. / Yasuhara, Takao; Shingo, Tetsuro; Date, Isao.

In: Acta Medica Okayama, Vol. 61, No. 2, 04.2007, p. 51-56.

Research output: Contribution to journalArticle

@article{c2842266709741d299df79ad5c9ea084,
title = "Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease",
abstract = "Many studies using animals clarify that glial cell line-derived neurotrophic factor (GDNF) has strong neuroprotective and neurorestorative effects on dopaminergic neurons. Several pilot studies clarified the validity of continuous intraputaminal GDNF infusion to patients with Parkinson's disease (PD), although a randomized controlled trial of GDNF therapy published in 2006 resulted in negative outcomes, and controversy remains about the efficacy and safety of the treatment. For a decade, our laboratory has investigated the efficacy and the most appropriate method of GDNF administration using animals, and consequently we have obtained some solid data that correspond to the results of clinical trials. In this review, we present an outline of our studies and other key studies related to GDNF, the current state of the research, problems to be overcome, and predictions regarding the use of GDNF therapy for PD in the future. Copyright",
keywords = "Cell transplantation, Clinical trial, Encapsulation, Gene therapy, Neurodegenerative disease",
author = "Takao Yasuhara and Tetsuro Shingo and Isao Date",
year = "2007",
month = "4",
language = "English",
volume = "61",
pages = "51--56",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "2",

}

TY - JOUR

T1 - Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease

AU - Yasuhara, Takao

AU - Shingo, Tetsuro

AU - Date, Isao

PY - 2007/4

Y1 - 2007/4

N2 - Many studies using animals clarify that glial cell line-derived neurotrophic factor (GDNF) has strong neuroprotective and neurorestorative effects on dopaminergic neurons. Several pilot studies clarified the validity of continuous intraputaminal GDNF infusion to patients with Parkinson's disease (PD), although a randomized controlled trial of GDNF therapy published in 2006 resulted in negative outcomes, and controversy remains about the efficacy and safety of the treatment. For a decade, our laboratory has investigated the efficacy and the most appropriate method of GDNF administration using animals, and consequently we have obtained some solid data that correspond to the results of clinical trials. In this review, we present an outline of our studies and other key studies related to GDNF, the current state of the research, problems to be overcome, and predictions regarding the use of GDNF therapy for PD in the future. Copyright

AB - Many studies using animals clarify that glial cell line-derived neurotrophic factor (GDNF) has strong neuroprotective and neurorestorative effects on dopaminergic neurons. Several pilot studies clarified the validity of continuous intraputaminal GDNF infusion to patients with Parkinson's disease (PD), although a randomized controlled trial of GDNF therapy published in 2006 resulted in negative outcomes, and controversy remains about the efficacy and safety of the treatment. For a decade, our laboratory has investigated the efficacy and the most appropriate method of GDNF administration using animals, and consequently we have obtained some solid data that correspond to the results of clinical trials. In this review, we present an outline of our studies and other key studies related to GDNF, the current state of the research, problems to be overcome, and predictions regarding the use of GDNF therapy for PD in the future. Copyright

KW - Cell transplantation

KW - Clinical trial

KW - Encapsulation

KW - Gene therapy

KW - Neurodegenerative disease

UR - http://www.scopus.com/inward/record.url?scp=34248570313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248570313&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 51

EP - 56

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 2

ER -